Susquehanna International Group
ATRA icon

Susquehanna International Group’s Atara Biotherapeutics ATRA Stock Holding History

Susquehanna International Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-928
Closed -$76.1K – 12531
2022
Q4 		$76.1K Buy
928
+504
+119% +$52.5K ﹤0.01% 11176
2022
Q3 		$40K Buy
+424
New +$47.6K ﹤0.01% 12327
2020
Q4 		– Sell
-3,168
Closed -$1.03M – 10984
2020
Q3 		$1.03M Buy
3,168
+1,416
+81% +$482K ﹤0.01% 6051
2020
Q2 		$638K Buy
1,752
+160
+10% +$40.4K ﹤0.01% 6844
2020
Q1 		$339K Buy
1,592
+148
+10% +$47K ﹤0.01% 7739
2019
Q4 		$595K Sell
1,444
-500
-26% -$172K ﹤0.01% 6604
2019
Q3 		$686K Buy
1,944
+1,064
+121% +$397K ﹤0.01% 6571
2019
Q2 		$442K Sell
880
-3,620
-80% -$2.56M ﹤0.01% 7523
2019
Q1 		$4.47M Sell
4,500
-444
-9% -$413K ﹤0.01% 2588
2018
Q4 		$4.29M Buy
4,944
+3,364
+213% +$3.12M ﹤0.01% 2463
2018
Q3 		$1.63M Sell
1,580
-3,608
-70% -$3.53M ﹤0.01% 4330
2018
Q2 		$4.77M Sell
5,188
-8,284
-61% -$8.9M ﹤0.01% 2767
2018
Q1 		$13.1M Buy
13,472
+11,840
+725% +$10.8M ﹤0.01% 1558
2017
Q4 		$738K Buy
1,632
+540
+49% +$199K ﹤0.01% 5844
2017
Q3 		$452K Sell
1,092
-1,164
-52% -$439K ﹤0.01% 6686
2017
Q2 		$790K Buy
2,256
+1,228
+119% +$473K ﹤0.01% 5754
2017
Q1 		$528K Buy
+1,028
New +$426K ﹤0.01% 6377
2016
Q1 		– Sell
-324
Closed -$214K – 8973
2015
Q4 		$214K Buy
324
+68
+27% +$51.4K ﹤0.01% 8309
2015
Q3 		$201K Sell
256
-156
-38% -$190K ﹤0.01% 8692
2015
Q2 		$543K Buy
+412
New +$473K ﹤0.01% 7474

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's ATRA Position: Q1 2026 in Review

Susquehanna International Group sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 14,018 shares — an estimated $254K sold.

Susquehanna International Group first reported a position in ATRA in Q4 2014 and held it in 27 quarters. The position peaked at $2M in Q4 2021. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Susquehanna International Group reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 14,018 Atara Biotherapeutics shares in Q1 2026, an estimated $254K.
  • Susquehanna International Group first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 27 quarters.
  • Susquehanna International Group's Atara Biotherapeutics position peaked at $2M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.